Page 51 - 2021_05-Haematologica-web
P. 51
CUDC-907 combined with venetoclax in AML
(Figure 2C), suggesting that the combination spares normal hematopoietic progenitors. In order to further determine the effect of the combination therapy on leukemia progen- itor/stem cells, primary AML cells were incubated with or without the human bone marrow stromal cell line HS-5. After allowing the cells to co-incubate for 24 hours, the cells were treated with CUDC-907 and venetoclax, alone or combined, for 24 hours and then measured the effects of
these drug treatments on CD34+ AML progenitor/stem cells. CUDC-907 and venetoclax co-operated in inducing Annexin V positivity in these AML progenitor/stem cells in the absence of HS-5 cells (Online Supplementary Figure S2). Interestingly, the combination of CUDC-907 and veneto- clax was still able to induce Annexin V positivity in these AML progenitor/stem cells even in the presence of HS-5 cells, though to a lesser extent.
A
B
Figure 5. Legend on next page.
haematologica | 2021; 106(5)
1271
